Literature DB >> 11996015

Summary of information on human CYP enzymes: human P450 metabolism data.

Slobodan Rendic1.   

Abstract

This chapter is an update of the data on substrates, reactions, inducers, and inhibitors of human CYP enzymes published previously by Rendic and DiCarlo (1), now covering selection of the literature through 2001 in the reference section. The data are presented in a tabular form (Table 1) to provide a framework for predicting and interpreting the new P450 metabolic data. The data are formatted in an Excel format as most suitable for off-line searching and management of the Web-database. The data are presented as stated by the author(s) and in the case when several references are cited the data are presented according to the latest published information. The searchable database is available either as an Excel file (for information contact the author), or as a Web-searchable database (Human P450 Metabolism Database, www.gentest.com) enabling the readers easy and quick approach to the latest updates on human CYP metabolic reactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996015     DOI: 10.1081/dmr-120001392

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  171 in total

Review 1.  Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations.

Authors:  Bella Pajares; Esperanza Torres; José Manuel Trigo; María Isabel Sáez; Nuria Ribelles; Begoña Jiménez; Emilio Alba
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

2.  Imidazopyridines as selective CYP3A4 inhibitors.

Authors:  Xinyi Song; Xiaohai Li; Claudia H Ruiz; Yan Yin; Yangbo Feng; Theodore M Kamenecka; Michael D Cameron
Journal:  Bioorg Med Chem Lett       Date:  2012-01-04       Impact factor: 2.823

Review 3.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

4.  Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

Authors:  Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh
Journal:  Pharm Res       Date:  2012-03-14       Impact factor: 4.200

5.  A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Authors:  Su-Jun Lee; Yin Jin Jang; Eun-Young Cha; Ho-Sook Kim; Sang Seop Lee; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 6.  Bioavailability challenges associated with development of anti-cancer phenolics.

Authors:  Song Gao; Ming Hu
Journal:  Mini Rev Med Chem       Date:  2010-06       Impact factor: 3.862

7.  Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Bernard H Shapiro
Journal:  Endocrinology       Date:  2011-09-27       Impact factor: 4.736

Review 8.  Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene.

Authors:  Slobodan P Rendic; Frederick P Guengerich
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

9.  Use of Phenoxyaniline Analogues To Generate Biochemical Insights into the Interactio n of Polybrominated Diphenyl Ether with CYP2B Enzymes.

Authors:  Chao Chen; Jingbao Liu; James R Halpert; P Ross Wilderman
Journal:  Biochemistry       Date:  2017-12-19       Impact factor: 3.162

10.  Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.

Authors:  Jyothi C Talakad; Santosh Kumar; James R Halpert
Journal:  Drug Metab Dispos       Date:  2008-12-12       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.